Venous thromboembolism prophylaxis effective in pediatric trauma patients: JAMA

A new study published in the Journal of American Medical Association suggests the use of chemical venous thromboembolism prophylaxis (cVTE) in pediatric trauma patients which was safe and did not result in bleeding issues. Recently, a set of high-risk guidelines for the use of cVTE was proposed which did not undergo a prospective evaluation. In order to investigate high-risk criteria and the usage of cVTE in a prospective multi-institutional study of pediatric trauma patients, Amanda Witte and colleagues undertook this study.

8 independent pediatric hospitals that have been recognized as level I pediatric trauma centers by the American College of Surgeons hosted this cohort research, which was finished between October 2019 and October 2022. The participants were juvenile trauma patients under the age of 18 who, satisfied certain high-risk criteria at admission. The idea was that cVTE would be risk-free and lower the prevalence of VTE. Receiving and timing chemical VTE prophylaxis was the primary exposure. The total VTE rate, stratified by the time and receipt of cVTE, was the main outcome. The safety of cVTE as determined by bleeding or other anticoagulation-related problems was the secondary endpoint.

The median (IQR) age of the 460 high-risk pediatric trauma patients was 14.5 years, of which, 313 patients (68%) were male and 147 patients (32%) were female. The number of high-risk variables were 3, and the median (IQR) Injury Severity Score (ISS) was 23 (16–30). 62(13.5%) of the 251 (54.5%) patients who had cVTE received it within 24 hours of their arrival. The patients with greater ISS and more high-risk characteristics were the individuals who underwent cVTE after a 24-hour period. The bleeding in the central nervous system was the most frequent cause of delayed cVTE.

Out of 25 patients, there were 28 VTE episodes (5.4%). Of 62 patients (1.6%) who received cVTE within 24 hours, 13 of 189 patients (6.9%) who had cVTE after 24 hours, and 11 of 209 (5.3%) who did not get cVTE, only one patient experienced VTE. A longer period of time between admission and the start of cVTE was substantially linked to VTE. While receiving cVTE, no bleeding problems were observed in the patients. Overall, the results suggests it is safe to use VTE prophylaxis in pediatric trauma patients at high risk and future research should concentrate on the best time to start prophylaxis and how to overcome obstacles to following recommendations.

Source:

Witte, A. B., Van Arendonk, K., Bergner, C., Bantchev, M., Falcone, R. A., Jr, Moody, S., Hartman, H. A., Evans, E., Thakkar, R., Patterson, K. N., Minneci, P. C., Mak, G. Z., Slidell, M. B., Johnson, M., Landman, M. P., Markel, T. A., Leys, C. M., Cherney Stafford, L., Draper, J., … Ehrlich, P. F. (2024). Venous Thromboembolism Prophylaxis in High-Risk Pediatric Trauma Patients. In JAMA Surgery. American Medical Association (AMA). https://doi.org/10.1001/jamasurg.2024.2487

Powered by WPeMatico

Declining oral health may predict mental health issue including depression: Study

Declining oral health may predict mental health issues including depression suggests a study published in the JDR Clinical & Translational Research

Individuals with mental illness have poor oral health compared to those without mental health conditions. However, the literature is still lacking regarding the specifics of this relationship. This study aims to examine the relationship between depression and oral health problems such as oral conditions, access to dental care, and oral hygiene measures. A cross-sectional study using a secondary data analysis of 9,693 participants from the 2017 to March 2020 prepandemic National Health and Nutrition Examination Survey (NHANES). The independent variable was severity of depressive symptoms as measured by the Patient Health Questionnaire–9 (PHQ-9). Proportional odds and binary logistic regression were used to calculate crude and adjusted odds ratios (AORs) between depression and 8 oral health outcomes and oral hygiene–related behaviors. Results: After adjusting for sociodemographics, health conditions, and behaviors, individuals with depression were significantly more likely to have dental aches in the past year (AOR = 1.70; 95% confidence interval [CI], 1.13–2.56), difficulty getting dental care when needed (AOR = 1.93; 95% CI, 1.45–2.58), and difficulty at their jobs due to a problem in their mouth (AOR = 1.63; 95% CI, 1.07–2.49) compared to individuals without depression. Individuals with depressive symptoms often neglect oral hygiene and self-care practices and are less likely to seek medical care for oral health problems, making them at increased risk of poor oral health outcomes. These findings can be applied by dentists, psychologists, and therapists to increase awareness of links between depression and oral health and to encourage patients with depression to seek oral hygiene preventative care.

Reference:

Bafageeh F, Loux T. Depression Symptoms Linked to Multiple Oral Health Outcomes in US Adults. JDR Clinical & Translational Research. 2024;0(0). doi:10.1177/23800844241246225

Keywords:

Declining, oral, health, predict, mental health issue, including, depression, study, Khan, M.S., Lea, J.P, Bafageeh F, Loux T

Powered by WPeMatico

Elevated BP in Pregnancy Linked to Long-Term Cardiometabolic Risks, reveals study

USA: A recent study published in Obstetrics & Gynecology has found a progressively higher frequency of adverse cardiometabolic outcomes at 10–14 years after delivery among pregnant women with blood pressure (BP) higher than 120/80 in the early third trimester.

Pregnancy is a transformative time for women, marked by various physiological changes, including alterations in BP. Elevated blood pressure during pregnancy, including conditions like gestational hypertension and preeclampsia, not only poses immediate risks to maternal and fetal health but also has long-term implications for cardiometabolic health.

Against the above background, Christine Field, Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, The Ohio State University, Columbus, OH, and colleagues aimed to investigate the association between elevated BP in the early third trimester and cardiometabolic health 10–14 years after delivery.

For this purpose, the researchers conducted a secondary analysis of the prospective HAPO FUS study. In the early third trimester, blood pressure levels were categorized according to the thresholds established by the American College of Cardiology/American Heart Association. These classifications are as follows: normal BP defined as below 120/80 mm Hg (considered as the reference range), elevated BP falls within the range of 120-129 systolic and below 80 diastolic mm Hg, stage 1 hypertension ranges from 130-139 systolic or 80-89 diastolic mm Hg, and stage 2 hypertension is characterized by 140 mm Hg systolic or higher and 90 mm Hg diastolic or higher.

Cardiometabolic outcomes were evaluated 10–14 years post the index pregnancy, focusing on type 2 diabetes mellitus and markers of dyslipidemia. Dyslipidemia measures included LDL cholesterol levels of 130 mg/dL or higher, total cholesterol levels of 200 mg/dL or higher, HDL cholesterol levels of 40 mg/dL or lower, and triglyceride levels of 200 mg/dL or higher. Adjusted analysis accounted for several covariates: study field center, duration of follow-up, age, body mass index (BMI), height, family history of hypertension and diabetes, smoking and alcohol consumption, parity, and oral glucose tolerance test glucose z score. These factors were considered to account for potential confounding variables and ensure a comprehensive assessment of the long-term health impacts following the initial pregnancy.

The study led to the following findings:

· Among 4,692 pregnant individuals at a median gestational age of 27.9 weeks, 8.5% had elevated BP, 14.9% had stage 1 hypertension, and 6.4% had stage 2 hypertension.

· At a median follow-up of 11.6 years, among individuals with elevated BP, there was a higher frequency of diabetes (elevated BP: adjusted relative risk [aRR] 1.88; stage 1 hypertension: aRR 2.58; stage 2 hypertension: aRR 2.83) compared with those with normal BP.

· Among individuals with elevated BP, there was a higher frequency of elevated LDL cholesterol (elevated BP: aRR 1.27; stage 1 hypertension: aRR 1.22, and stage 2 hypertension: aRR 1.38), elevated total cholesterol (elevated BP: aRR 1.27; stage 1 hypertension: aRR 1.16; stage 2 hypertension: aRR 1.41), and elevated triglycerides (elevated BP: aRR 2.24; stage 1 hypertension: aRR 2.15; stage 2 hypertension: aRR 3.24) but not of low HDL cholesterol.

“The frequency of adverse cardiometabolic outcomes at 10–14 years after delivery was progressively higher among pregnant individuals with BP greater than 120/80 mm Hg in the early third trimester,” the researchers concluded.

Reference:

Field, Christine MD, MPH; Grobman, William A. MD, MBA; Wu, Jiqiang MSc; Kuang, Alan MSc; Scholtens, Denise M. PhD; Lowe, William L. MD; Shah, Nilay S. MD; Khan, Sadiya S. MD, MSc; Venkatesh, Kartik K. MD, PhD. Elevated Blood Pressure in Pregnancy and Long-Term Cardiometabolic Health Outcomes. Obstetrics & Gynecology ():10.1097/AOG.0000000000005674, July 16, 2024. | DOI: 10.1097/AOG.0000000000005674

Powered by WPeMatico

Post excision radiotherapy useful adjuvant treatment option for refractory keloids: Study

Post-excision radiotherapy useful adjuvant treatment option for refractory keloids suggests a study published in the Dermatology.

Keloid is an abnormal proliferation of scar tissue that grows beyond the original margins of the injury. Even after complete resection, recurrences are common and pose a poorly understood challenge in dermatology. There is lack of large prospective clinical trials; thus, treatment recommendations are based on retrospective analyses and small cohort studies. Superficial radiotherapy is recommended in recurrent keloids; however, the successful treatment rates vary greatly. The aim of this study was to evaluate the keloid recurrence rate after post-excision soft X-ray radiotherapy and the associated factors. Methods: We reviewed retrospective data of all patients, treated with adjuvant post-excision soft X-ray radiotherapy with 12 Gy in 6 sessions at the tertiary referral center, Department of Dermatology, University Hospital Zurich, Switzerland, between 2005 and 2018. We analyzed individual keloids as separate cases. Successful treatment was defined as no sign of recurrence within 2 years. Results: Of the 200 identified patients, 90 met the inclusion criteria and were included in the final analysis. In 90 patients, 104 cases of treated keloids were analyzed. Keloids were mainly located on the trunk (49%) and were mostly caused by previous surgery (52.2%). 50% of the keloids did not relapse within 2 years after therapy. A significant factor leading to recurrence was the presence of previous therapy, with prior topical therapies, such as steroid injections or 5-fluorouracil, leading to most relapses. 69.2% of keloid cases who relapsed were pretreated. Soft X-ray radiotherapy was well tolerated, with posttreatment hyperpigmentation noted in 34% of patients, particularly in patients with non-Caucasian origin (61.3%). Treatment of refractory keloids is difficult. Post-excision radiotherapy is an established adjuvant treatment option; nevertheless, recurrence rates are high, especially in pretreated keloids. Prospective studies determining the exact dosage and fraction of post-excisional radiotherapy are needed to determine the optimal radiation parameters.

Reference:

Egle Ramelyte, Michèle Welti, Fabian Gardin, Julia-Tatjana Maul, Reinhard Dummer, Laurence Imhof; Post-Excision Soft X-Ray Radiotherapy for Keloids: Experience in a Tertiary Referral Center. Dermatology 2024; https://doi.org/10.1159/000539782

Keywords:

Egle Ramelyte, Michèle Welti, Fabian Gardin, Julia-Tatjana Maul, Reinhard Dummer, Laurence Imhof; Post-Excision, Soft X-Ray, Radiotherapy, Keloids, Experience, Tertiary Referral Center, Dermatology 2024

Powered by WPeMatico

Endovascular Thrombectomy may Yield Long-Term Benefits for Large Infarct Stroke Patients: Lancet

Researchers in a recent study indicated that endovascular thrombectomy offered long-term benefits to acute ischemic stroke patients having large vessel occlusion and large infarct. As per the 12-month follow-up analysis for the TENSION trial, prominent, lasting improvements in functional outcomes, quality of life, and overall survival were noted for acute ischemic attack patients due to large vessel occlusion. The findings were published in the Lancet Neurology journal by Prof. Gotz Thomalla and colleagues.

The challenge persists in the management of chronic stroke, especially in patients with large infarcts. Endovascular thrombectomy had certain promising early results in recent studies, but long-term data has been scant. TENSION trailed this gap, examining for safety and effectiveness, up to 12 months, endovascular thrombectomy in patients with large infarcts.

The TENSION trial was an open-label, blinded endpoint randomized trial conducted in 40 hospitals in Europe and one in Canada. The patients were 18 years or older with acute ischemic anterior circulation stroke, large vessel occlusion identified by an Alberta Stroke Program Early Computed Tomographic Score of 3-5. Patients were randomly assigned to receive endovascular thrombectomy and medical treatment versus medical treatment alone within 12 hours of stroke onset.

The primary outcome was the functional outcome measured by the modified Rankin Scale at 90 days. The 12-month follow-up included assessments of functional outcome, quality of life (using PROMIS-10 and EQ-5D questionnaires), post-stroke anxiety and depression (using PHQ-4), and overall survival.

Results

The trial randomized 253 patients from July 17, 2018, to February 21, 2023, when it was stopped because of demonstrated efficacy. Of those, 125 (49%) received endovascular thrombectomy with 128 (51%) receiving medical treatment only. Median follow-up time was 8.36 months.

The key findings at 12 months were:

  • On the modified Rankin Scale, endovascular thrombectomy showed better functional outcomes; the common odds ratio after adjustment was 2.39 with a 95% confidence interval of 1.47 to 3.90.

  • Scores on quality of life were better in the thrombectomy group, with a median 0.7 EQ-5D index score and an IQR of 0.4 to 0.9, compared with 0.4, IQR 0.2-0.7, for those who had medical treatment.

  • Health status on the EQ-5D visual analogue scale was 50 (IQR, 35-70) versus 30 (IQR, 5-60), and PROMIS-10 global physical health scores were 39.8 (IQR, 37.4-50.8) versus 37.4 (IQR, 32.4-44.9).

  • There was no significant difference in global mental health scores on PROMIS-10 (41.1 [IQR, 36.3-48.3] vs. 38.8 [IQR, 31.3-44.7]).

  • Anxiety and depression were reported by 22% and 31% of thrombectomy patients, respectively, compared to 42% and 50% in the medical treatment group.

  • Survival was slightly better in the thrombectomy group, with an adjusted hazard ratio of 0.70 (95% CI, 0.50-0.99).

Results from the TENSION trial show that very long-term benefits of endovascular thrombectomy exist in patients with large infarcts from acute ischemic stroke. There were major improvements in functional and quality-of-life outcomes and survival, which underpin the use of thrombectomy in this patient group. However, no significant difference was observed in the mental health outcome, and it seems that further interventions might be needed in respect to anxiety and depression following a stroke.

Reference:

Thomalla, G., Fiehler, J., Subtil, F., Bonekamp, S., Aamodt, A. H., Fuentes, B., Gizewski, E. R., Hill, M. D., Krajina, A., Pierot, L., Simonsen, C. Z., Zeleňák, K., Blauenfeldt, R. A., Cheng, B., Denis, A., Deutschmann, H., Dorn, F., Flottmann, F., Gellißen, S., … Zubel, S. (2024). Endovascular thrombectomy for acute ischaemic stroke with established large infarct (TENSION): 12-month outcomes of a multicentre, open-label, randomised trial. Lancet Neurology. https://doi.org/10.1016/s1474-4422(24)00278-3

Powered by WPeMatico

NBE Invites Applications from hospitals, institutes seeking Accreditation For DrNB, FNB, DNB courses July-August 2024 cycle, all details here

New Delhi- Applications are invited from Hospitals, Institutes and Medical Institutions for accreditation with the National Board of Examinations in Medical Sciences (NBEMS) of Super Specialty courses (DrNB), Fellowship Courses (FNB) and Broad Speciality (DNB) including Direct 6 years courses.

For the accreditation, the Hospitals, Institutes and Medical Institutions can submit the application form including payment of fees till 30th September 2024. Meanwhile, the last date for receipt of Hard Copy (Spiral Bind) (Both Main and Specialty Specific Applications separately) at the NBEMS Office is scheduled till 15 October 2024.

Applicant hospitals/institutes are required to submit the application form online through the Online Accreditation Application Portal (OAAP) as per the steps indicated below.

STEP 1- Create a User – Online.

STEP 2- Create a profile of the applicant hospital – Online. The hospital profile will be verified by NBEMS. The applicant hospital cannot submit the application unless the profile is verified by NBEMS.

STEP 3- Fill out the Main application form & Specialty Application form online – (Click here for details).

STEP 4- Complete the application form and upload the Annexure / Documents – Online.

STEP 5- Fee payment through online payment portal – Online.

STEP 6- Print and submit the hard copy of the Main & Specialty Application form (separately) – Offline.

In this regard, NBEMS has released an information bulletin, detailing the Accreditation. The information bulletin includes details such as DNB, DrNB & FNB Courses, Applying for NBEMS Accreditation, Minimum Accreditation Criteria, Guidelines for Accredited HospitalDistrict DNB/DrNB Programme at State Government owned District/ General/ Civil hospitals, Communication Protocol for Accreditation Purposes and Sponsored Seats.

As per the information bulletin, the Hospitals/Institutes accredited till June 2025 for Super-specialty courses and Fellowship courses may apply for renewal of accreditation. Hospitals/Institutes accredited till December 2024 for Broad specialty courses including Direct 6 years courses may also apply for renewal of accreditation.

Applicant hospitals/institutes seeking fresh accreditation or renewal of accreditation in any speciality are required to pay an accreditation fee of Rs. 2,00,000/- Plus GST @ 18% for each speciality-specific application. The application form fee for each speciality-specific application is Rs. 3,000/- Plus GST @ 5%.

The total fee to be paid for each specialty-specific application is as follows:

S.NO

PARTICULARS

FEES

1

Accreditation Fee for each Specialty

Rs 2,00,000/-

2

GST @ 18% on Accreditation fee

Rs. 36,000/-

3

Application Form Fee

Rs. 3,000/-

4

GST @ 5% on Accreditation fee

Rs. 150/

5

Total fee to be paid per specialty

Rs. 2,39,150/-

A partial refund of the Accreditation Fee is admissible under the following conditions-

S.NO

Refund of Accreditation Fee

Terms & Conditions

1

90% of total fee

-If the application is withdrawn by the applicant hospital/institute within 4 weeks of last date of online application submission to NBEMS

– Incomplete applications which are summarily rejected without subjecting them to a detailed “Pre-assessment processing”

2

50% of total fee

· If the application is withdrawn by the applicant hospital / institute after 4 weeks of last date for online application submission to NBEMS, but before the physical assessment/inspection of the applicant department by NBEMS appointed assessor.

· If the application is rejected at pre-assessment level (prior to physical assessment/inspection of the department by NBEMS appointed assessor) due to nonfulfilment of minimum accreditation criteria and/or the hospital fails to submit definite compliance within the stipulated time (if so required) to the Pre – Assessment deficiencies communicated to the hospital by NBEMS.

3

No refund shall be admissible

·Once the physical assessment/inspection of the applicant department has been conducted by NBEMS appointed assessor.

NBEMS accredits hospitals/institutions for running DNB/DrNB/FNB/Diploma courses in various Broad & Super Specialty and Fellowship courses. It offers a total of 106 subjects in DNB, DRNB and FNB courses. Of these, 31 subjects are in DNB, 28 in DRNB, 4 in direct 6-year course and 43 in FNB. In addition, NBEMS has also introduced Post MBBS 02 years Diploma (NBEMS) courses in the following nine Broad specialities-

S.NO

SPECIALITY

NAME OF THE QUALIFICATION

1

Anaesthesiology

DA (NBEMS)

2

Obstetrics & Gynaecology

DGO (NBEMS)

3

Paediatrics

DCH (NBEMS)

4

Family Medicine

DFam.Med (NBEMS)

5

Ophthalmology

DO (NBEMS)

6

Otorhinolaryngology (ENT)

DLO (NBEMS)

7

Radio Diagnosis

DMRD (NBEMS)

8

Tuberculosis & Chest Disease

DTCD (NBEMS)

9

Emergency Medicine

DEM (NBEMS)

To view the Information Bulletin, click the link below

Powered by WPeMatico

Submit clinical study data conducted in adults: CDSCO Panel Tells Sanofi on atopic dermatitis drug

New Delhi: Responding to the protocol amendment proposal for Amlitelimab study, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined the drug major Sanofi that the data of clinical studies conducted in adults shall be submitted to CDSCO for further review by the committee before enrolment of adolescents and subjects less than 40 kg in weight.

This came after the drug maker Sanofi presented clinical trial Phase III protocol amendment 01 version 01 dated 20.11.2023 (protocol No. EFC17559). This is a phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of Amlitelimab monotherapy by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis.

Amlitelimab, a human anti-OX40 ligand monoclonal antibody, is under development for the treatment of atopic dermatitis, hidradenitis suppurativa, asthma, alopecia areata, celiac disease, and systemic sclerosis. Amlitelimab’s mechanism focuses on OX40-Ligand and is tailored to recalibrate the balance between the body’s pro-inflammatory and regulatory T cells.

At the recent meeting for Dermatology and Allergy held on July 11, 2024, the expert panel reviewed the clinical trial Phase III protocol amendment 01 version 01 dated 20.11.2023 (protocol No. EFC17559).

After detailed deliberation, the committee opined that the data of the clinical study conducted in adults should be submitted to CDSCO for further review by the committee before enrolling adolescents and subjects less than 40 kg.

Also Read: Eli Lilly Gets CDSCO Panel Nod to Study Retatrutide

Powered by WPeMatico

Death Due to Medical Negligence during Blood Transfusion: Private Hospital, Doctors slapped Rs 20 Lakh Compensation

Coimbatore: The District Consumer Disputes Redressal Commission (DCDRC), Coimbatore recently directed a hospital and three doctors to pay Rs 20 lakh as compensation to a man, whose wife died due to medical negligence during a blood transfusion.

While considering the matter, the consumer court observed that proper informed consent was not obtained and required tests were not conducted before the transfusion and even though the patient complained of body pain, the transfusion was not immediately stopped. Following the transfusion, the patient developed TRALI (Transfusion-Related Acute Lung Injury) and consequently died. 

The history of the case goes back to 2018 when the complainant’s wife was injured after falling from a scooter. She sustained injuries in her mouth part and face fracture neck Condylar process to mandible with dislocation noted on the right side, and undisplaced linear fracture in the angle of right side of mandible extending to the socket of last molar tooth.

Consequently, the Facio Maxillary surgeon suggested open reduction and internal fixation (ORIF) for putting pieces of broken bones into place by screws to hold the broken bone together and intermaxillary fixation. He also advised the complainant to admit the patient to the treating hospital for ORIF surgery in his care and gave a reference letter to admit the patient. 

Before the surgery, blood cells were arranged for blood transfusion purposes. However, after the transfusion started, the patient felt body and leg pain and informed the same to the duty nurse. It was alleged that she was not attended to by any doctor.

After the blood transfusion stopped, the Medical Officer Dr. Selvan came to the hospital and informed the other doctors about it. Based on the advice by Dr. Antony, another Medical officer, Dr. Selvan gave injections to the patient. However, the patient was running a heavy fever and her condition worsened. Further medications were given. Allegedly, the doctors and the hospital neither gave any emergency medical aid nor shifted the patient to any multi-speciality hospital. The patient’s condition became worse and she was taken to the Intensive Care Unit. However, the patient did not recover and she died.

The medical certificate issued by the doctors mentioned that the patient had died due to “Sudden Cardio respiratory arrest”. After the police complaint filed by the complainant, a postmortem was conducted by the associate professor H.Q.D of forensic medicine at Coimbatore Medical College and he opined that the patient had died due to “transfusion related acute lung injury (TRALI) caused by blood transfusion done for surgical repair of the fractured mandible.

Filing the consumer complaint, the complainant alleged that the doctors and the hospital were negligent, careless and reckless and they did not follow the standard procedure mentioned for transfusion practices and did not take steps to resolve the complication immediately to save the patient’s life.

On the other hand, the doctors and the hospital submitted that before starting the blood transfusion all tests were done as per the standard practice. It was further submitted that the patient had an immune-mediated process that could not be identified before the transfusion. They claimed that there was no medical negligence on their end and despite the best treatment given, the patient suffered a medical accident and unfortunately passed away.

It was submitted that for 80-85% of patients, antibodies are produced due to immune mediation, sometimes occurring in individuals with more than one pregnancy. When such blood is transfused, it can lead to TRALI (Transfusion-Related Acute Lung Injury). TRALI can also occur in those with lung diseases. Non-immune mechanisms can also trigger TRALI in some cases. It was claimed that the TRALI incident during the packed cell transfusion was not due to their negligence, as proper treatment was provided according to medical standards.

The complainant had also submitted a complaint to the District Collector of Coimbatore who instructed the Joint Director of Medical and Health Services Department to conduct enquiry. The Joint Director after conducting enquiry with the complainant and the treating doctors and hospital, filed a report stating that the complainant’s wife died due to Transfusion-Related Acute Lung Injury and rejected the petition. This was also highlighted by one of the doctors before the consumer court.

While considering the matter, the Consumer Court reviewed relevant medical literature and observed that while TRALI can indeed be caused by various factors and is considered a medical emergency, the question involved in this case was not the cause for TRALI but whether the standard procedure was followed before, during and after the blood transfusion.

Regarding the complainant’s allegation that no informed consent was obtained for blood transfusion, the Commission noted that the hospital, which claimed to have obtained the consent letter, did not produce it and no such letter was produced by the dentist as well. 

“There is no explanation for not providing the consent letter, much less an acceptable one. From this, it is evident that OP3 did not obtain the consent letter before transfusing blood,” it noted.

Citing clause 11.1.1 of Chapter 11 “Bed-Side Transfusion Practices” of Standards for Blood Banks and Blood Transfusion Services published by the National AIDS Control Organization, Ministry of Health and Family Welfare, New Delhi, the Commission observed,

“OPs did not obtain consent, much less informed consent, before the blood transfusion, which is in contravention of the standard procedure…”

“The Hon’ble Supreme Court in Samira Kohli v. Dr. Prabha Manchanda has held that consent in the context of a doctor-patient relationship means the grant of permission by the patient for an act to be carried out by the doctor, such as a diagnostic, surgical, or therapeutic procedure. What is relevant and important is the inviolable nature of the patient’s right regarding his body and his right to decide whether he should undergo a particular treatment or surgery. The nature of the information required to be furnished by a doctor to secure valid or real consent is crucial. The Hon’ble Supreme Court in the case of M. Chinniyan v. Sri Gokulam Hospital cited by the complainant elaborated on the importance of obtaining informed consent. In the present case, there is no informed consent before the blood transfusion, and it amounts to a deficiency in service and negligence by OP1 to OP3,” it further noted.

The consumer court noted that before a blood transfusion, two blood tests known as “type and cross match” are done. A “cross match” is performed to ensure that the donor red blood cells (RBCs) are compatible with the recipient’s serum. To perform a cross-match, a small amount of the recipient’s serum is mixed with a small amount of the donor’s RBCs. The mixture is then examined under a microscope to check for agglutination or hemolysis.

After going through the doctor’s note and the nurse’s chart, the Commission noted, 

“…it is revealed that there are no details regarding the conduct of compatibility tests and cross matches performed. The OPs did not submit any material to suggest that they performed these tests. Therefore, their failure to conduct these prescribed pre-transfusion tests is considered negligence and a deficiency in service.”

Further, the consumer court noted that there was negligence by the doctors during the blood transfusion as well. The Commission observed that “…despite the patient’s complaints of body and leg pain at 11:30 PM, the transfusion was not discontinued until 11:45 PM.”

Referring to the evidence of Dr. K. C. Usha, the Professor and Head of Transfusion Medicine at Medical College Hospital, Thiruvananthapuram, as cited by the Hon’ble NCDRC in the case of Samad Hospital Vs. Muhammed Basheer, the Commission noted that the doctors and hospital “did not provide any material to substantiate that they acted according to the guidelines outlined by Dr. Usha after the transfusion reaction. Even the medical literature produced by the OPs suggests that transfusion reactions should be managed as per the aforementioned medical practice.”

“Transfusion reactions and adverse events should be investigated by the clinical team and hospital transfusion team and reviewed by the hospital transfusion committee. There is no material available to suggest that the above procedures were followed. Therefore, the contention of OP1 to OP4 that they provided appropriate and proper treatment by following the standard medical procedure is untenable. Consequently, the Commission finds that OP1 to OP4 committed a breach of duty while treating the complainant’s wife after she complained of a blood transfusion reaction,” further observed the Commission.

The Commission noted that since the complainant demonstrated that the doctors and hospital did not follow standard medical procedures before and during the transfusion, the principle of res ipsa loquitur should be invoked.

Therefore, holding the doctors and hospital guilty of medical negligence, the consumer directed them to pay Rs 20 lakh compensation to the complainant. It ordered, “In the result, this complaint is partly allowed directing the opposite parties 1 to 4 who are jointly and severally liable i) to pay a sum of Rs.20,00,000/- (Rupees Twenty Lakhs only) as compensation to the complainant for the mental suffering, emotional trauma caused by their negligence and deficiency in service, and ii) to pay a sum of Rs.5000/- (Rupees Five thousand only) towards the cost of proceedings. The above amounts to be paid within a period of one month from the date of this order failing which the opposite parties 1 to 4 shall be liable to pay interest at the rate of 9% p.a. towards the above said total amount till it is realized. The complaint as against the 5th opposite party is dismissed.”

To read the order, click on the link below:

https://medicaldialogues.in/pdf_upload/coinbatore-consumer-court-245565.pdf

Also Read: Needle Left in Abdomen During Surgery: Consumer Court Directs Bengaluru Hospital, Doctors to Pay Rs 5 Lakh Compensation to patient

Powered by WPeMatico

CDSCO Panel Approves Eli Lilly’s Protocol Amendment proposal to study Antidiabetic Drug Tirzepatide

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has approved the protocol amendment proposal presented by drug major Eli Lilly to study the antidiabetic drug Tirzepatide.

This came after drug maker Eli Lilly presented protocol amendment (b) dated 24 April 2024 protocol no. I8F-MC-GPIJ.

Tirzepatide is in a class of medications called glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonists.

Tirzepatide activation of GIP receptors augments insulin sensitivity and secretion and thereby helps reinforce the mechanisms regulating blood glucose levels.Tirzepatide activation of GIP receptors augments insulin sensitivity and secretion and thereby helps reinforce the mechanisms regulating blood glucose levels.

Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclinical and clinical trials.

At the recent SEC meeting for Endocrinology and Metabolism held on July 11, 2024, the expert panel reviewed the proposal presented by the drug major Eli Lilly for the protocol amendment (b) dated 24 April 2024 protocol no. I8F- MC-GPIJ.

After detailed deliberation, the committee recommended the approval of the protocol amendment as presented by the firm.

Also Read: Zydus Life Sciences Gets CDSCO Panel Nod to Study anti-cancer drug Relugolix

Powered by WPeMatico

CDSCO panel Approves Novartis Protocol Amendment proposal to study inclisiran

New Delhi: The Subject Expert Committee SEC functional under the Central Drug Standard Control Organization (CDSCO) has approved the drug major Novartis’s protocol amendment proposal to study KJX839 (inclisiran), the first and only small interfering RNA (siRNA) therapy to reduce low-density lipoprotein cholesterol (LDL-C) levels.

This came after the firm presented protocol amendment version 01 dated 16.08.2023 and protocol amendment version 02 dated 23.11.2023 for protocol No. CKJX839D12303.

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase IIIb study evaluating the effect of inclisiran on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of non-obstructive coronary artery disease without previous cardiovascular events (VICTORION-PLAQUE).

KJX839, also known as inclisiran is a long-acting, synthetic small interfering RNA (siRNA) directed against the proprotein convertase subtilisin-kexin type 9 (PCSK9), which is a serine protease that regulates plasma low-density lipoprotein cholesterol (LDL-C) levels. By binding to PCSK9 messenger RNA, inclisiran prevents protein translation of PCSK9, leading to decreased concentrations of PCSK9 and plasma concentrations of LDL cholesterol.

At the recent SEC meeting for cardiovascular held on July 16, 2024, the expert panel reviewed protocol amendment version 01 dated 16.08.2023 and protocol amendment version 02 dated 23.11.2023 for protocol No. CKJX839D12303 presented by the drug major Novartis.

After detailed deliberation, the committee recommended the approval of the protocol amendment as presented by the firm.

Also Read: CDSCO Panel Approves AstraZeneca’s Protocol Amendment Proposal to Study anti-cancer Drug Capivasertib

Powered by WPeMatico